Chiusolo, P., Salutari, P., Sica, S., Scirpa, P., Laurenti, L., Piccirillo, N., & Leone, G. (1998). Luteinizing hormone-releasing hormone analogue: Leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplantation, 21, 821–823.

Low-dose leuprorelin acetate (Lupron^®) 3.75 mg given subcutaneously at least 30 days prior to transplant conditioning regimen and the second injection given 28 days after the first
 

• N = 30
• FEMALES: 100%
• OTHER KEY SAMPLE CHARACTERISTICS: Premenopausal females undergoing bone marrow or peripheral blood stem cell transplantation with high-dose conditioning chemotherapy

• Menstrual bleeding and vaginal spotting during thrombocytopenia were assessed.
• Long-term outcomes related to menstrual status were assessed via measurement of luteinizing hormone, follicle-stimulating hormone, and estradiol measures, but these outcomes are not of interest to this review.

Mean duration of thrombocytopenia was 28 days; only one patient developed menstrual bleeding during this time. No side effects related to leuprorelin acetate were noted.